These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37993023)

  • 21. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
    Tap WD; Healey JH
    Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
    Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
    Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.
    Möller E; Mandahl N; Mertens F; Panagopoulos I
    Genes Chromosomes Cancer; 2008 Jan; 47(1):21-5. PubMed ID: 17918257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Keratin-Positive Giant Cell-Rich Tumor of Bone Harboring an
    Patton A; Ilaslan H; Armstrong SM; Bakhshwin A; Cheng YW; Minhas F; Fritchie KJ
    Int J Surg Pathol; 2024 May; 32(3):556-564. PubMed ID: 37461232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
    Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
    Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenosynovial giant cell tumor.
    Kager M; Kager R; Fałek P; Fałek A; Szczypiór G; Niemunis-Sawicka J; Rzepecka-Wejs L; Starosławska E; Burdan F
    Folia Med Cracov; 2022; 62(2):93-107. PubMed ID: 36256897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation.
    Huang HY; West RB; Tzeng CC; van de Rijn M; Wang JW; Chou SC; Huang WW; Eng HL; Lin CN; Yu SC; Wu JM; Lu CC; Li CF
    Clin Cancer Res; 2008 Oct; 14(19):6023-32. PubMed ID: 18829481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The macrophage colony-stimulating factor 1 response signature in breast carcinoma.
    Beck AH; Espinosa I; Edris B; Li R; Montgomery K; Zhu S; Varma S; Marinelli RJ; van de Rijn M; West RB
    Clin Cancer Res; 2009 Feb; 15(3):778-87. PubMed ID: 19188147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Giant cell-rich tumour with keratin expression and HMGA2::NCOR2 fusion presenting at a rare location, on the scalp of a 29-year-old male.
    Wilsher MJ; Venus M; Fisher C
    Pathology; 2024 Jun; 56(4):609-612. PubMed ID: 38341304
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors.
    Panagopoulos I; Brandal P; Gorunova L; Bjerkehagen B; Heim S
    Int J Oncol; 2014 May; 44(5):1425-32. PubMed ID: 24604026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors.
    van IJzendoorn DGP; Matusiak M; Charville GW; Spierenburg G; Varma S; Colburg DRC; van de Sande MAJ; van Langevelde K; Mohler DG; Ganjoo KN; Bui NQ; Avedian RS; Bovée JVMG; Steffner R; West RB; van de Rijn M
    Clin Cancer Res; 2022 Nov; 28(22):4934-4946. PubMed ID: 36007098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the molecular spectrum of tenosynovial giant cell tumors.
    Gauduchon T; Vanacker H; Pissaloux D; Cassier P; Dufresne A; Karanian M; Meurgey A; Bouhamama A; Gouin F; Ray-Coquard I; Blay JY; Tirode F; Brahmi M
    Front Oncol; 2022; 12():1012527. PubMed ID: 36439507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer.
    Okugawa Y; Toiyama Y; Ichikawa T; Kawamura M; Yasuda H; Fujikawa H; Saigusa S; Ohi M; Araki T; Tanaka K; Inoue Y; Tanaka M; Miki C; Kusunoki M
    Int J Oncol; 2018 Aug; 53(2):737-749. PubMed ID: 29767252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.